Glycan Therapeutics

Glycan Therapeutics is a biotechnology company focused on the development of synthetic carbohydrate-based therapeutics, particularly heparin and heparan sulfate analogs. The company utilizes a proprietary chemoenzymatic synthesis platform to create homogeneous, well-defined glycans that serve as safer alternatives to animal-derived products. Their research pipeline includes novel anticoagulants designed to minimize bleeding risks and glycan-based treatments for inflammatory diseases and viral infections. Additionally, Glycan Therapeutics provides specialized glycan reagents and analytical services to support the broader glycobiology research community. By leveraging precise molecular engineering, the company aims to address unmet needs in hematology, oncology, and infectious diseases.